The article in Vox Sanguinis discusses a meta-analysis of studies on the efficacy and safety of pathogen-reduced platelet concentrates in patients with chemotherapy-induced thrombocytopenia. The authors analyzed trials of Intercept and Mirasol PC for bleeding prevention compared to standard platelets, with some separate analyses for each method of pathogen inactivation. The article raises questions about the rationale for the subgroup analyses, discrepancies in trial data, and the importance of transparent reporting in clinical trials. The authors declare no conflicts of interest, and data sharing was not applicable to the study. [Extracted from the article]

Copyright of Vox Sanguinis is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)